143 related articles for article (PubMed ID: 22616710)
1. Mantle-cell lymphoma in the elderly: is it time to CHOP and change?
Farrell K; Rule S
Leuk Lymphoma; 2012 Oct; 53(10):1855-6. PubMed ID: 22616710
[No Abstract] [Full Text] [Related]
2. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
[No Abstract] [Full Text] [Related]
3. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by
Smith MR; Hong F; Li H; Gordon LI; Gascoyne RD; Paietta EM; Advani RH; Forero-Torres A; Horning SJ; Kahl BS
Leukemia; 2017 Feb; 31(2):517-519. PubMed ID: 27780968
[No Abstract] [Full Text] [Related]
4. Haematological cancer: Bortezomib in MCL--new standard of care or just another option?
Dreyling M
Nat Rev Clin Oncol; 2015 Jul; 12(7):376-8. PubMed ID: 26011491
[No Abstract] [Full Text] [Related]
5. Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma.
Pessach I; Petevi K; Gkirkas K; Stamouli M; Constantinou P; Rontogianni D; Dimitriadis G; Tsirigotis P
Leuk Lymphoma; 2016 Nov; 57(11):2702-4. PubMed ID: 26999270
[No Abstract] [Full Text] [Related]
6. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytarabine in mantle cell lymphoma.
Martin P
Clin Adv Hematol Oncol; 2015 Oct; 13(10):646-9. PubMed ID: 27058567
[No Abstract] [Full Text] [Related]
8. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T; Huang H; Jin J; Zhu J; Liu T; Samoilova O; Pylypenko H; Verhoef G; Siritanaratkul N; Osmanov E; Alexeeva J; Pereira J; Drach J; Mayer J; Hong X; Okamoto R; Pei L; Rooney B; van de Velde H; Cavalli F;
N Engl J Med; 2015 Mar; 372(10):944-53. PubMed ID: 25738670
[TBL] [Abstract][Full Text] [Related]
9. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
10. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
Räty R; Honkanen T; Jantunen E; Jyrkkiö S; Karjalainen-Lindsberg ML; Kuittinen O; Lehto M; Mikkola M; Poikonen E; Rauhala A; Rimpiläinen J; Räsänen A; Siitonen S; Suominen M; Vapaatalo M; Elonen E
Leuk Lymphoma; 2012 Oct; 53(10):1920-8. PubMed ID: 22397313
[TBL] [Abstract][Full Text] [Related]
11. Nonpolypoid intestinal mantle cell lymphoma resembling MALT lymphoma with successful response to rituximab.
D'Antonio A; Boscaino A; Addesso M; Liguori G; Nappi O
South Med J; 2008 Nov; 101(11):1168-9. PubMed ID: 19088534
[TBL] [Abstract][Full Text] [Related]
12. Point: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma: Where It Fits in the New Paradigm.
Goy A
Oncology (Williston Park); 2016 Dec; 30(12):1055-8, 1060. PubMed ID: 27987196
[No Abstract] [Full Text] [Related]
13. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
Thomas DW; Owen RG; Johnson SA; Hillmen P; Seymour JF; Wolf MM; Rule SA
Leuk Lymphoma; 2005 Apr; 46(4):549-52. PubMed ID: 16019483
[TBL] [Abstract][Full Text] [Related]
14. Optimal frontline management of mantle cell lymphoma: can we agree?
Tang C; Kuruvilla J
Expert Rev Hematol; 2018 Dec; 11(12):911-914. PubMed ID: 30336708
[No Abstract] [Full Text] [Related]
15. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
17. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Klener P; Fronkova E; Belada D; Forsterova K; Pytlik R; Kalinova M; Simkovic M; Salek D; Mocikova H; Prochazka V; Blahovcova P; Janikova A; Markova J; Obr A; Berkova A; Kubinyi J; Vaskova M; Mejstrikova E; Campr V; Jaksa R; Kodet R; Michalova K; Trka J; Trneny M
Hematol Oncol; 2018 Feb; 36(1):110-115. PubMed ID: 29083050
[TBL] [Abstract][Full Text] [Related]
18. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
19. What is the optimal initial management of the older MCL patient?
Kluin-Nelemans JC; Doorduijn JK
Best Pract Res Clin Haematol; 2018 Mar; 31(1):99-104. PubMed ID: 29452672
[TBL] [Abstract][Full Text] [Related]
20. Blurred Vision and Wrinkled Retinas in an Elderly Man.
Zhao PY; Kahana A; Kim TN
JAMA Ophthalmol; 2019 Feb; 137(2):226-227. PubMed ID: 30589928
[No Abstract] [Full Text] [Related]
[Next] [New Search]
